Zobrazeno 1 - 10
of 63
pro vyhledávání: '"James R. Kiefer"'
Autor:
Shravan Kumar Sriraman, Christopher W. Davies, Herman Gill, James R. Kiefer, Jianping Yin, Annie Ogasawara, Alejandra Urrutia, Vincent Javinal, Zhonghua Lin, Dhaya Seshasayee, Ryan Abraham, Phil Haas, Christopher Koth, Jan Marik, James T. Koerber, Simon Peter Williams
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 50:679-691
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f089c094378cad1bc4da07510270b743
https://doi.org/10.1007/s00259-022-05998-0
https://doi.org/10.1007/s00259-022-05998-0
Autor:
Emily J. Hanan, Marie-Gabrielle Braun, Robert A. Heald, Calum MacLeod, Connie Chan, Saundra Clausen, Kyle A. Edgar, Charles Eigenbrot, Richard Elliott, Nicholas Endres, Lori S. Friedman, Emily Gogol, Xiao-Hui Gu, Rebecca Hong Thibodeau, Philip S. Jackson, James R. Kiefer, Jamie D. Knight, Michelle Nannini, Raman Narukulla, Amanda Pace, Jodie Pang, Hans E. Purkey, Laurent Salphati, Deepak Sampath, Stephen Schmidt, Steve Sideris, Kyung Song, Swathi Sujatha-Bhaskar, Mark Ultsch, Heidi Wallweber, Jianfeng Xin, SiewKuen Yeap, Amy Young, Yu Zhong, Steven T. Staben
Publikováno v:
Journal of medicinal chemistry. 65(24)
Small molecule inhibitors that target the phosphatidylinositol 3-kinase (PI3K) signaling pathway have received significant interest for the treatment of cancers. The class I isoform PI3Kα is most commonly associated with solid tumors via gene amplif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::085a38e6723d04c169025fcfa48abbbc
https://pubmed.ncbi.nlm.nih.gov/36455032
https://pubmed.ncbi.nlm.nih.gov/36455032
Autor:
Jun Guo, Noel Dybdal, Ben-Quan Shen, Daniela Bumbaca Yadav, Gail Lewis Phillips, William R Proctor, James R. Kiefer
Publikováno v:
Breast Cancer Research and Treatment
Purpose Assessment of non-clinical safety signals relies on understanding species selectivity of antibodies. This is particularly important with antibody–drug conjugates, where it is key to determine target-dependent versus target-independent toxic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c0a2be5c2c0ef445b8d4efb083a45f2
http://europepmc.org/articles/PMC8763818
http://europepmc.org/articles/PMC8763818
Autor:
Annie, Ogasawara, James R, Kiefer, Herman, Gill, Eugene, Chiang, Shravan, Sriraman, Gregory Z, Ferl, James, Ziai, Sandra Sanabria, Bohorquez, Sebastian, Guelman, Xiangdan, Wang, Jihong, Yang, Minh Michael, Phan, Van, Nguyen, Shan, Chung, Christine, Yu, Jeff, Tinianow, Stijn Jan Hein, Waaijer, Alex, De Crespigny, Jan, Marik, C Andrew, Boswell, Tanja, Zabka, Karin, Staflin, Simon-Peter, Williams
Publikováno v:
European journal of nuclear medicine and molecular imaging. 50(2)
ZED8 is a novel monovalent antibody labeled with zirconium-89 for the molecular imaging of CD8. This work describes nonclinical studies performed in part to provide rationale for and to inform expectations in the early clinical development of ZED8, s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::31e464b63e7f56aaa5305457496e7b95
https://pubmed.ncbi.nlm.nih.gov/36427067
https://pubmed.ncbi.nlm.nih.gov/36427067
Autor:
Shravan Kumar, Sriraman, Christopher W, Davies, Herman, Gill, James R, Kiefer, Jianping, Yin, Annie, Ogasawara, Alejandra, Urrutia, Vincent, Javinal, Zhonghua, Lin, Dhaya, Seshasayee, Ryan, Abraham, Phil, Haas, Christopher, Koth, Jan, Marik, James T, Koerber, Simon Peter, Williams
Publikováno v:
European journal of nuclear medicine and molecular imaging.
Cancer immunotherapies (CITs) have revolutionized the treatment of certain cancers, but many patients fail to respond or relapse from current therapies, prompting the need for new CIT agents. CD8To this end, we discovered and developed a 13-kDa singl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9afa9b240811f5c84d5d69908a699efe
https://pubmed.ncbi.nlm.nih.gov/36346438
https://pubmed.ncbi.nlm.nih.gov/36346438
Autor:
Joseph W. Lubach, Jennifer Vogt, Wendy B. Young, Charles Eigenbrot, Arna Katewa, James J. Crawford, Dinah Misner, Harvey Wong, Hans E. Purkey, Wendy Lee, Adam R. Johnson, Karin Reif, Jacob Z. Chen, Satoko Kakiuchi-Kiyota, Lichuan Liu, Julia Heidmann, Christine Yu, James R. Kiefer, Kelly J. Delatorre
Publikováno v:
ACS Med Chem Lett
[Image: see text] Bruton’s tyrosine kinase (Btk) is thought to play a pathogenic role in chronic immune diseases such as rheumatoid arthritis and lupus. While covalent, irreversible Btk inhibitors are approved for treatment of hematologic malignanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::741c155f1116115d9a133dcec622d3c8
https://doi.org/10.1021/acsmedchemlett.0c00249
https://doi.org/10.1021/acsmedchemlett.0c00249
Autor:
Kuen Yeap, John S. Wai, Maia Vinogradova, Yu Zhong, Lori Friedman, Xiaojing Wang, Daniel Otwine, Jiangpeng Liao, Nick Ray, James R. Kiefer, Vidhi Mody, Jun Li, Fabien Roussel, Deepak Sampath, Simon Charles Goodacre, Jun Liang, Michelle Nannini, Sharada Labadie, Xiaoping Zheng, Ellen Ingalla, Steven J. Hartman, Birong Zhang, Jae H. Chang, Tao Wang, Yingqing Ran, Jason R. Zbieg, Amy Sambrone, Kwong Wah Lai, Amy Young, Ciara Metcalfe, Neville James Mclean, Robert A. Blake, Tracy Kleinheinz
Publikováno v:
ACS Med Chem Lett
[Image: see text] Estrogen receptor alpha (ERα) is a well-validated drug target for ER-positive (ER+) breast cancer. Fulvestrant is FDA-approved to treat ER+ breast cancer and works through two mechanisms—as a full antagonist and selective estroge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe42f6062f9f361a3f700a527fd2a8dc
https://doi.org/10.1021/acsmedchemlett.0c00224
https://doi.org/10.1021/acsmedchemlett.0c00224
Autor:
Annie Ogasawara, James R. Kiefer, Herman Gill, Eugene Chiang, Shravan Sriraman, Gregory Z. Ferl, James Ziai, Sandra Sanabria Bohorquez, Sebastian Guelman, Xiangdan Wang, Jihong Yang, Minh Michael Phan, Van Nguyen, Shan Chung, Christine Yu, Jeff Tinianow, Stijn Jan Hein Waaijer, Alex De Crespigny, Jan Marik, C. Andrew Boswell, Tanja Zabka, Karin Staflin, Simon‑Peter Williams
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 50:631-631
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6b98039043207e4c6ff9a61fb954259
https://doi.org/10.1007/s00259-022-06050-x
https://doi.org/10.1007/s00259-022-06050-x
Autor:
Satoko Kakiuchi-Kiyota, Thorsten Ross, Heidi Ackerly Wallweber, James R. Kiefer, Melissa M. Schutten, Adeyemi O. Adedeji, Hao Cai, Robert Hendricks, Sivan Cohen, Srividya Myneni, Luna Liu, Aaron Fullerton, Nicholas Corr, Lanlan Yu, Denise de Almeida Nagata, Shelly Zhong, Steven R. Leong, Ji Li, Rin Nakamura, Teiko Sumiyoshi, Jinze Li, Ayse Meric Ovacik, Bing Zheng, Mike Dillon, Christoph Spiess, Susanne Wingert, Erich Rajkovic, Kristina Ellwanger, Uwe Reusch, Andrew G. Polson
Publikováno v:
Leukemia. 36(4)
Despite the recent progress, multiple myeloma (MM) is still essentially incurable and there is a need for additional effective treatments with good tolerability. RO7297089 is a novel bispecific BCMA/CD16A-directed innate cell engager (ICE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff3f1955e5f0bd6496e5fba6012a99b1
https://pubmed.ncbi.nlm.nih.gov/35001074
https://pubmed.ncbi.nlm.nih.gov/35001074
Autor:
Martin O'Rourke, Nicholas Charles Ray, Thomas Gelzleichter, Leah Schutt, Ellen Ingalla, Neville James Mclean, Xiaojing Wang, Stephen Daly, Yingqing Ran, Jiangpeng Liao, Tommy Lai, Yu Zhong, Jun Liang, Sharada Labadie, Lori Friedman, Amy Sambrone, Jun Li, Robert A. Blake, Tao Wang, Liu Zhiguo, Birong Zhang, Steven J. Hartman, Jae H. Chang, Wei Zhou, Jane Guan, Vidhi Mody, Jonathan White, Fabien Roussel, Antonio G. DiPasquale, Jason R. Zbieg, Daniel F. Ortwine, Amy Young, James R. Kiefer, Maia Vinogradova, Simon Charles Goodacre, Deepak Sampath, Tracy Kleinheinz, Xiaoping Zheng, Jennifer M. Giltnane, Lorn Kategaya, Ingrid E. Wertz, Matthew Gill, Ciara Metcalfe, Siew Kuen Yeap, John S. Wai, Jason Oeh, Michelle Nannini
Publikováno v:
Journal of medicinal chemistry. 64(16)
Breast cancer remains a leading cause of cancer death in women, representing a significant unmet medical need. Here, we disclose our discovery efforts culminating in a clinical candidate, 35 (GDC-9545 or giredestrant). 35 is an efficient and potent s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee86fe3f8068fbb2ff9647a59eadb710
https://pubmed.ncbi.nlm.nih.gov/34251202
https://pubmed.ncbi.nlm.nih.gov/34251202